BAIAP2L2 and neoplasm: Future studies should focus on preclinical and clinical investigations to assess the therapeutic feasibility of BAIAP2L2 inhibition, its synergy with existing therapies (e.g., androgen deprivation therapy and immune checkpoint inhibitors), and its impact on tumor microenvironment interactions.